Viekira Pak and Technivie - FDA warns of serious liver injury risk with hepatitis C treatments
Seven patients on AbbVie Inc.’s drugs for hepatitis C died after liver failure, prompting U.S. regulators to change their advice on how the medicine should be administered.
Doctors should monitor patients using Viekira Pak for signs of worsening liver disease, the U.S. Food and Drug Administration said in a stateme - See more at:
http://www.hepatitiscnewdrugresearch.com/#.dpuf